Healius (ASX:HLS) confirmed that it signed a binding agreement to sell its Agilex Biolabs business to a unit of Novotech Health Holdings for an enterprise value of AU$160 million.
The company said the transaction represents a multiple of 19.8 times Agilex Biolabs' fiscal 2026 earnings before interest, taxes, depreciation and amortization on a pre-AASB16 basis, and is expected to generate cash proceeds of about AU$155 million after transaction and separation costs.
The pathology and imaging company does not expect to incur any tax in relation to the deal, with completion remaining subject to customary conditions including approval from the Foreign Investment Review Board and the Australian Competition and Consumer Commission.
Healius began exploring a sale of Agilex Biolabs in May after receiving several unsolicited approaches from "credible parties." The firm determined that a sale at a sufficiently attractive price would help focus on growing its core pathology business.
Healius expects to move to a net cash position once the deal completes, which it expects would be in the second half of fiscal 2027.
The Australian Financial Review reported on Thursday that Healius finalized the sale of Agilex Biolabs to Novotech, a clinical research organisation controlled by global buyout firm TPG and Singaporean investors GIC and Temasek.
According to AFR, other suitors in the sale process included Blackstone's clinical trials business Nucleus Network, global analytics and clinical research firm IQVIA, and US life sciences company Thermo Fisher Scientific.



